FDA Panel Backs Statin for Primary Prevention

WASHINGTON (MedPage Today) — An FDA advisory panel has overwhelminingly recommended that rousuvastatin (Crestor) be approved use in patients with no history of heart disease as long as the patients have an elevated level of the inflammatory marker C-reactive protein.

source : www.medpagetoday.com

Related News:

• Expectant moms who take probiotics have healthier babies
• Study Says More Research Needed To Verify Effectiveness Of ACL And Knee Injury Prevention Programs
• AP Reports On How Newly Approved Vaccine Could Revolutionize Prevention Of Meningitis In Africa
• Homocysteine Flops for MI Prevention
• GTx Announces Top Line Results Of Phase III Trial Evaluating Toremifene 20 Mg For The Prevention Of Prostate Cancer In Men With High Grade PIN
• HRS: Mixed Results for Fish Oil in AFib Prevention
• Prevention And Non-Surgical Treatment Effective For Most People Suffering From Low Back Pain Says The AANS
• Nutraceuticals And Prostate Cancer Prevention: A Current Review
• Child Abuse Prevention Month
• Diet and Lifestyle Still Top Bone Loss Prevention Strategies

Details :
Submited at Wednesday, December 16th, 2009 at 1:00 am on Cardiology by robert
Comment RSS 2.0 - leave a comment - trackback